Response to proposal for a novel cancer drug pricing model

Nat Rev Clin Oncol. 2018 Aug;15(8):528. doi: 10.1038/s41571-018-0062-7.

Authors

Toon van der Gronde^{1

2}, Hubertus G Leufkens², Toine Pieters³

Affiliations

¹ AstraZeneca, Cambridge, United Kingdom.
² Utrecht Institute for Pharmaceutical Sciences (UIPS) Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, Netherlands.
³ Utrecht Institute for Pharmaceutical Sciences (UIPS) Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, Netherlands. t.pieters@uu.nl.

PMID: 29955112
DOI: 10.1038/s41571-018-0062-7

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Agents*
Costs and Cost Analysis
Drug Costs*
Humans

Substances

Antineoplastic Agents